{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-26-000147","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.877944+00:00","generated_at":"2026-05-15T08:18:57.371142+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Vertex completes BLA submission for povetacicept in IgAN with priority review","bullets":["Submitted rolling Biologics Licensing Application to FDA for povetacicept to treat IgAN in adults.","Used a priority review voucher, reducing expected FDA review to 6 months from typical 10 months.","Submission seeks potential accelerated approval; no decision or timeline for acceptance yet.","Company notes forward-looking statements and risks including regulatory approval uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-26-000147","json":"https://secwatch.observer/filing/0000875320-26-000147.json","markdown":"https://secwatch.observer/filing/0000875320-26-000147.md","text":"https://secwatch.observer/filing/0000875320-26-000147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000147/0000875320-26-000147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000147/vrtx-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:18:57.371142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}